Astera Labs, Inc. $ALAB Shares Purchased by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. increased its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 8.9% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 25,403 shares of the company’s stock after buying an additional 2,080 shares during the period. Stratos Wealth Partners LTD.’s holdings in Astera Labs were worth $2,297,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of ALAB. Straight Path Wealth Management increased its stake in shares of Astera Labs by 1.5% in the second quarter. Straight Path Wealth Management now owns 6,850 shares of the company’s stock worth $619,000 after acquiring an additional 100 shares during the period. Wealthcare Advisory Partners LLC boosted its holdings in Astera Labs by 0.8% in the second quarter. Wealthcare Advisory Partners LLC now owns 29,160 shares of the company’s stock valued at $2,637,000 after purchasing an additional 221 shares during the last quarter. Allworth Financial LP grew its position in Astera Labs by 20.4% during the 1st quarter. Allworth Financial LP now owns 1,394 shares of the company’s stock worth $90,000 after purchasing an additional 236 shares during the period. Sound Income Strategies LLC raised its stake in shares of Astera Labs by 31.1% during the 2nd quarter. Sound Income Strategies LLC now owns 1,038 shares of the company’s stock valued at $94,000 after buying an additional 246 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Astera Labs by 55.7% in the 1st quarter. GAMMA Investing LLC now owns 794 shares of the company’s stock valued at $47,000 after buying an additional 284 shares during the period. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Astera Labs Stock Down 2.3%

Astera Labs stock opened at $159.80 on Monday. Astera Labs, Inc. has a 52-week low of $47.13 and a 52-week high of $262.90. The firm has a market capitalization of $26.56 billion, a price-to-earnings ratio of 285.36, a PEG ratio of 3.98 and a beta of 1.43. The company has a fifty day simple moving average of $199.68 and a 200-day simple moving average of $128.80.

Astera Labs (NASDAQ:ALAB) last released its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.11. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The business had revenue of $191.93 million during the quarter, compared to analyst estimates of $172.46 million. During the same quarter in the prior year, the firm earned $0.13 earnings per share. The company’s revenue for the quarter was up 149.5% compared to the same quarter last year. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. On average, research analysts anticipate that Astera Labs, Inc. will post 0.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on ALAB shares. Northland Capmk lowered Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 22nd. Morgan Stanley lifted their price objective on shares of Astera Labs from $155.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, August 29th. Evercore ISI lifted their price objective on shares of Astera Labs from $104.00 to $215.00 and gave the company an “outperform” rating in a report on Wednesday, August 6th. TD Cowen initiated coverage on shares of Astera Labs in a report on Wednesday, October 1st. They issued a “hold” rating and a $200.00 price objective for the company. Finally, CICC Research initiated coverage on shares of Astera Labs in a report on Friday, August 29th. They issued an “outperform” rating and a $190.00 price objective for the company. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $162.06.

Insider Buying and Selling at Astera Labs

In other news, CFO Michael Truett Tate sold 18,861 shares of the company’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $183.51, for a total transaction of $3,461,182.11. Following the completion of the sale, the chief financial officer owned 259,512 shares of the company’s stock, valued at $47,623,047.12. This represents a 6.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Philip Mazzara sold 10,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $192.16, for a total transaction of $1,921,600.00. Following the completion of the sale, the general counsel directly owned 151,573 shares of the company’s stock, valued at $29,126,267.68. This represents a 6.19% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,092,997 shares of company stock valued at $192,231,120. 12.50% of the stock is owned by company insiders.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.